calcitriol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Vitamin D analogues/derivatives 466 32222-06-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rocaltrol
  • calcitriol
  • Dihydroxyvitamin D3
  • topitriol
  • 1,25-dihydroxyvitamin D3
The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.
  • Molecular weight: 416.65
  • Formula: C27H44O3
  • CLOGP: 6.04
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 3
  • TPSA: 60.69
  • ALOGS: -4.80
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mcg O
1 mcg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 61 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.25 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.31 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 11 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 17, 1978 FDA VALIDUS PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypercalcaemia 845.34 47.75 126 312 2466 2355181
Milk-alkali syndrome 285.10 47.75 34 404 82 2357565
Arteriovenous fistula site complication 212.65 47.75 27 411 125 2357522
Acute kidney injury 187.69 47.75 55 383 28067 2329580
Hospitalisation 125.05 47.75 35 403 14818 2342829
Calciphylaxis 85.45 47.75 14 424 443 2357204
Nephrocalcinosis 81.58 47.75 12 426 183 2357464
Metabolic alkalosis 53.08 47.75 9 429 350 2357297
Hypervitaminosis D 49.96 47.75 6 432 15 2357632

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hospitalisation 254.02 69.04 62 280 12638 1733801
Hypercalcaemia 234.27 69.04 42 300 1844 1744595
Arteriovenous fistula site complication 197.41 69.04 27 315 182 1746257
Mitral valve thickening 115.77 69.04 13 329 7 1746432
Ventricular hyperkinesia 112.87 69.04 13 329 12 1746427
Right atrial enlargement 110.94 69.04 13 329 16 1746423
Hypochromasia 105.82 69.04 13 329 30 1746409
Left ventricular enlargement 103.35 69.04 13 329 39 1746400
Left atrial enlargement 101.93 69.04 13 329 45 1746394
Mean platelet volume increased 100.86 69.04 13 329 50 1746389
Blood phosphorus increased 90.96 69.04 15 327 382 1746057
Hypervolaemia 89.58 69.04 13 329 137 1746302
Blood chloride increased 79.82 69.04 13 329 305 1746134
Red cell distribution width increased 76.52 69.04 13 329 397 1746042
Blood creatinine increased 76.19 69.04 25 317 13921 1732518
Hypertensive heart disease 74.91 69.04 13 329 451 1745988
Aortic valve incompetence 74.83 69.04 14 328 746 1745693
Electrocardiogram T wave inversion 74.83 69.04 13 329 454 1745985
Tricuspid valve incompetence 73.83 69.04 15 327 1231 1745208
Diastolic dysfunction 73.51 69.04 13 329 504 1745935
Blood urea increased 72.96 69.04 19 323 4692 1741747
Blood iron decreased 72.29 69.04 13 329 555 1745884
Eosinophil count increased 72.08 69.04 15 327 1386 1745053
High density lipoprotein decreased 70.38 69.04 13 329 645 1745794
Blood pressure systolic decreased 69.69 69.04 13 329 681 1745758

Pharmacologic Action:

SourceCodeDescription
ATC A11CC04 ALIMENTARY TRACT AND METABOLISM
VITAMINS
VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO
Vitamin D and analogues
ATC D05AX03 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR TOPICAL USE
Other antipsoriatics for topical use
FDA CS M0004229 Cholecalciferol
FDA EPC N0000175908 Vitamin D3 Analog
MeSH PA D050071 Bone Density Conservation Agents
MeSH PA D002120 Calcium Channel Agonists
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018977 Micronutrients
CHEBI has role CHEBI:50733 nutraceutical
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:50846 immunomodulator
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50646 bone density conservation agent
MeSH PA D014662 Vasoconstrictor Agents
MeSH PA D014815 Vitamins

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypophosphatemia indication 4996001
Hypocalcemia indication 5291005
Renal osteodystrophy indication 16726004 DOID:13068
Hypoparathyroidism indication 36976004 DOID:11199
Plaque psoriasis indication 200965009
Hyperparathyroidism Secondary to Chronic Renal Failure indication
Hypocalcemia from End-Stage Renal Disease with Dialysis indication
Neonatal hypocalcemic tetany off-label use 18442000
Vitamin D deficiency off-label use 34713006
Rickets off-label use 41345002 DOID:10609
Familial x-linked hypophosphatemic vitamin D refractory rickets off-label use 82236004
Vitamin D Dependent Rickets off-label use
Hyperphosphatemia contraindication 20165001 DOID:0050459
Hypervitaminosis D contraindication 27712000 DOID:9971
Sarcoidosis contraindication 31541009 DOID:11335
Hypercalcemia contraindication 66931009 DOID:12678
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Arteriosclerosis obliterans contraindication 361133006 DOID:5160
Hypercalcemia associated with Sarcoidosis contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.7 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Vitamin D3 receptor Nuclear hormone receptor AGONIST EC50 8.40 WOMBAT-PK CHEMBL
Vitamin D 25-hydroxylase Enzyme WOMBAT-PK
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Enzyme WOMBAT-PK
Vitamin D-binding protein Secreted Kd 7.62 CHEMBL
Vitamin D3 receptor Transcription factor EC50 10.30 CHEMBL
Vitamin D3 receptor Unclassified Kd 10.15 CHEMBL
Vitamin D3 receptor Transcription factor Ki 10.30 CHEMBL
Vitamin D3 receptor Transcription factor Ki 10.60 CHEMBL
Vitamin D3 receptor A Nuclear hormone receptor EC50 8.26 CHEMBL

External reference:

IDSource
D002117 MESH_DESCRIPTOR_UI
4017800 VUID
N0000146161 NUI
C0006674 UMLSCUI
D00129 KEGG_DRUG
259333003 SNOMEDCT_US
68206008 SNOMEDCT_US
4017800 VANDF
001017 NDDF
42410 MMSL
1894 RXNORM
4324 MMSL
d03126 MMSL
CHEMBL846 ChEMBL_ID
DB00136 DRUGBANK_ID
FXC9231JVH UNII
4393 INN_ID
CHEBI:17823 CHEBI
2779 IUPHAR_LIGAND_ID
5280453 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 0054-0007 CAPSULE 0.25 ug ORAL ANDA 17 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 0054-3120 SOLUTION 1 ug ORAL ANDA 14 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 0093-7352 CAPSULE, LIQUID FILLED 0.25 ug ORAL ANDA 13 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 0093-7353 CAPSULE, LIQUID FILLED 0.50 ug ORAL ANDA 13 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 0143-9728 INJECTION 1 ug INTRAVENOUS ANDA 12 sections
Vectical HUMAN PRESCRIPTION DRUG LABEL 1 0299-2012 OINTMENT 3 ug TOPICAL NDA 16 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 17478-831 INJECTION 1 ug INTRAVENOUS ANDA 12 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 17478-931 INJECTION 1 ug INTRAVENOUS ANDA 12 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 17478-932 INJECTION 2 ug INTRAVENOUS ANDA 12 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 17856-0723 CAPSULE 0.25 ug ORAL ANDA 13 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 17856-3120 SOLUTION 1 ug ORAL ANDA 14 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 23155-118 CAPSULE, LIQUID FILLED 0.25 ug ORAL ANDA 11 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 23155-119 CAPSULE, LIQUID FILLED 0.50 ug ORAL ANDA 11 sections
CALCITRIOL HUMAN PRESCRIPTION DRUG LABEL 1 23155-662 CAPSULE 0.25 ug ORAL ANDA 12 sections
CALCITRIOL HUMAN PRESCRIPTION DRUG LABEL 1 23155-663 CAPSULE 0.50 ug ORAL ANDA 12 sections
Rocaltrol HUMAN PRESCRIPTION DRUG LABEL 1 30698-143 CAPSULE, GELATIN COATED 0.25 ug ORAL NDA 12 sections
Rocaltrol HUMAN PRESCRIPTION DRUG LABEL 1 30698-144 CAPSULE, GELATIN COATED 0.50 ug ORAL NDA 12 sections
Rocaltrol HUMAN PRESCRIPTION DRUG LABEL 1 30698-911 SOLUTION 1 ug ORAL NDA 12 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 43353-034 CAPSULE 0.25 ug ORAL ANDA 18 sections
CALCITRIOL HUMAN PRESCRIPTION DRUG LABEL 1 43353-138 CAPSULE 0.25 ug ORAL NDA authorized generic 13 sections
Rocaltrol HUMAN PRESCRIPTION DRUG LABEL 1 43353-633 CAPSULE, GELATIN COATED 0.25 ug ORAL NDA 13 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 43353-998 CAPSULE, LIQUID FILLED 0.25 ug ORAL ANDA 12 sections
calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 45802-608 OINTMENT 3 ug TOPICAL NDA 17 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 51407-169 CAPSULE, LIQUID FILLED 0.25 ug ORAL ANDA 11 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 51407-170 CAPSULE, LIQUID FILLED 0.50 ug ORAL ANDA 11 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 54868-4582 CAPSULE, LIQUID FILLED 0.50 ug ORAL ANDA 12 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 54868-4584 CAPSULE, LIQUID FILLED 0.25 ug ORAL ANDA 12 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 54868-6265 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 12 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 60687-345 CAPSULE 0.25 ug ORAL ANDA 13 sections
Calcitriol HUMAN PRESCRIPTION DRUG LABEL 1 62756-967 CAPSULE, LIQUID FILLED 0.25 ug ORAL ANDA 12 sections